Empagliflozin Increases Cardiac Energy Production in Diabetes Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

Overview of attention for article published in JACC: Basic to Translational Science, August 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#27 of 815)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet
twitter: 184 X users

facebook: 2 Facebook pages

Citations

dimensions_citation: 290 Dimensions

Readers on

mendeley: 193 Mendeley

Summary News X Facebook Dimensions citations

So far, Altmetric has seen 2 public wall posts from 2 users.

Medicina Mi Pasion Y Vida - Medicina Interna Hcv, 30 Oct 2018

Editors’ Insights: Can SGLT2 inhibitor empagliflozin increase ATP production and prevent heart failure in a mouse diabetic model?

JACC Journals - Journals of the American College of Cardiology, 29 Oct 2018

Editors’ Insights: Can SGLT2 inhibitor empagliflozin increase ATP production and prevent heart failure in a mouse diabetic model?

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.